| Item type |
☆紀要論文 / Departmental Bulletin Paper(1) |
| 公開日 |
2015-02-12 |
| タイトル |
|
|
タイトル |
Usefulness of rituximab-based treatment of seven patients with WaldenstrÖm macroglobulinemia |
|
言語 |
en |
| 著者 |
Ueda, Koji
Murakami, Haruo
Wada, Yusuke
Nagare, Yasuaki
Urase, Fumiaki
|
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
rituximab, fludarabine, waldenstrÖm macroglobulinemia |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 著者 所属 |
|
|
値 |
Department of Hematology, Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology, Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology, Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology, Sakai Hospital, Kinki University Faculty of Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology, Sakai Hospital, Kinki University Faculty of Medicine |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 著者所属(翻訳) |
|
|
値 |
Kinki University |
| 版 |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| 出版者 名前 |
|
|
出版者 |
Kinki University Medical Association |
| 書誌情報 |
en : ACTA MEDICA KINKI UNIVERSITY
巻 39,
号 2,
p. 83-87,
発行日 2014-12-01
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03866092 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
[Abstract] Waldenstrom macroglobulinemia is relatively rare, accounting for approximately 2% of all hematological malignancies, with an annual incidence of 2-3 per million, median age at presentation of 64 years, and overall survival of 60 months. The aim of treatment should be to improve the quality and duration of life with minimal side effects in the most cost-effective manner. We retrospectively investigated the clinical characteristics and treatment of seven elderly patients with WaldenstrÖm macroglobulinemia in our institute. The median age of patients was 72 years (range: 62-77) and median serum IgM level was 2,975 mg/dL (range: 1033-6806). 3 patients were treated with rituximab alone (375 mg/m^2, once a month for 8 months), and 4 patients were treated with rituximab 375 mg/m^2 on day 1 and oral fludarabine 25 mg/m^2 on days 2-6 every 4 weeks for 6 courses. Rituximab alone was effective, with 1 CR, 1 PR, and 1 SD, and no toxicity being reported. The rituximab and fludarabine treatment was also effective, with 4 PR. The maintoxicity observed was hematological, and there were no severe infections. The rituximab and fludarabine treatment was an effective therapy; however, myelosuppression may pose a problem in patients. Patients can tolerate long-term treatment with the clinically stable rituximab alone, which is necessary to investigate the optimal regimen and maintenance therapy for rituximab. |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
AA0050842X-20141200-0083.pdf (450.0 kB)
